Working… Menu

Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia (ADVANCE-II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03697707
Recruitment Status : Recruiting
First Posted : October 5, 2018
Last Update Posted : September 18, 2019
VU University Medical Center
Information provided by (Responsible Party):
DCPrime BV